Clinical Trials · NCT04153929
A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Boehringer Ingelheim
- Enrollment
- 413
- Start date
- Apr 2020
- Locations
- 80 sites, 14 countries
- Primary endpoint
- Absolute Change in HbA1c From Baseline to 16 Weeks